$1.36-12.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2.2M | $208K | +952.88% |
| Profit | -$1.6M | -$3.5M | +54.93% |
| Profit per share | -$0.24 | -$3.46 | +93.06% |
| Free Cash Flow | -$1.5M | -$2.6M | +41.83% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Technologies, Inc. Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for medical and other specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY™ technology platform being developed for biocomposite and 3D printing applications.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from SINTX Technologies, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
SINTX Technologies, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From SINTX Technologies, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$2.2M
+385% q/q
Guided
—
No guide given
Actual
-$0.24
Guided
—
No guide given
Actual
-$1.6M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.